The impetus to explore OGA inhibition as a therapeutic strategy for AD stemmed from two independent works (33, 75) that showed human tau was O-GlcNAc modified and that aggregates of tau within AD brain had no associated O-GlcNAc. The gene discussed is OGA; the disease is Alzheimer disease.